共 34 条
[1]
Narasimhalu K(2020)Cost effectiveness of genotype-guided antiplatelet therapy in Asian ischemic stroke patients: ticagrelor as an alternative to clopidogrel in patients with CYP2C19 loss of function mutations Clin Drug Investig. 94 317-323
[2]
Ang YK(2013)Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update Clin Pharmacol Ther. 12 e0169233-335
[3]
Tan DSY(2017)Analysis of genetic variation in CYP450 genes for clinical implementation PLoS ONE 11 e002253-6192
[4]
De Silva DA(2018)Letter by Aw et al regarding article, "clinical outcomes and sustainability of using CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention" Circ Genom Precis Med. 58 332-13208
[5]
Tan KB(2004)Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects [published correction appears in Br J Clin Pharmacol. 2004 Dec;58(6):680. Yang, YS [corrected to Pang, YS]] Br J Clin Pharmacol. 23 6186-176
[6]
Scott SA(2017)Analysis of CYP2C19 genetic polymorphism in a large Ethnic Hakka Population in Southern China Med Sci Monit. 8 13201-217
[7]
Sangkuhl K(2015)Genetic polymorphisms and phenotypic analysis of drug-metabolizing enzyme CYP2C19 in a Li Chinese population Int J Clin Exp Pathol. 5 159-undefined
[8]
Stein CM(2020)Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of ischaemic cerebrovascular diseases Stroke Vasc Neurol. 383 207-undefined
[9]
Goh LL(2020)Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA N Engl J Med. undefined undefined-undefined
[10]
Lim CW(undefined)undefined undefined undefined undefined-undefined